DAVID B. CASE, M.D.; JOHN H. LARAGH, M.D.
Baseline plasma renin activity and responses to saralasin and converting enzyme inhibitor SQ 20881 (teprotide) in 47 untreated patients with surgically correctable renovascular hypertension were compared to those in 100 patients with high- and normal-renin essential hypertensioopn. All 32 renovascular patients on normal sodium intake had high renin-sodium profiles and renin values ≥ 5 ng angiotensin l/mL·h, as compared to 20 of 64 with essential hypertension. Diagnostic discrimination was greatly enhanced by infusion of saralasin or SQ 20881, which elicited marked reactive hyperreninemia in 31 of 32 renovascular patients but in only two of 64 with essential hypertension. Reactive hyperreninemia appeared to be more a specific test for renovascular hypertension than depressor responses. Prior dietary sodium depletion abolished this specificity. The results suggest that after initial screening with renin measurements, testing with angiotensin blocking agents may be a useful secondary screening procedure for more invasive and definitive procedures.
DAVID B. CASE, JOHN H. LARAGH. Reactive Hyperreninemia in Renovascular Hypertension After Angiotensin Blockade with Saralasin or Converting Enzyme Inhibitor. Ann Intern Med. 1979;91:153–160. doi: 10.7326/0003-4819-91-2-153
Download citation file:
Published: Ann Intern Med. 1979;91(2):153-160.
Adrenal Disorders, Cardiology, Coronary Risk Factors, Endocrine and Metabolism, Hypertension.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use